Urologists Invest in Imagin Medical Private Placement

Medical Device Investing

Imagine Medical (CSE:IME; OTC:IMEXF) has announced it received approval from the University of Rochester for the upcoming in-human Research STudy using the i/Blue Imaging System to detect bladder cancer. As quoted in the press release: The of closing of Tranche I of Imagin’s recently announced and oversubscribed Private Placement further advances the Company’s on-going development …

Imagine Medical (CSE:IME; OTC:IMEXF) has announced it received approval from the University of Rochester for the upcoming in-human Research STudy using the i/Blue Imaging System to detect bladder cancer.
As quoted in the press release:

The of closing of Tranche I of Imagin’s recently announced and oversubscribed Private Placement further advances the Company’s on-going development plan. Investors in this Private Placement include urologists Dr. Stan Swierzewski, Chief of Surgery & Director of Urology at Holyoke Medical Center in Massachusetts, and Dr. Roger Buckley, Division Head of Urology at North York General Hospital in Toronto.

Dr. Stanley J Swierzewski offered the following comments: “As a practicing urologist, I invested in Imagin because I have a duty and responsibility to advance any improvements in treatment and technology that will benefit my patients and save lives. Current technology is cumbersome and time consuming, taking a full hour of prep time as opposed to 10 minutes, making it less effective as a screening or follow-up tool. Bladder cancer patients are basically monitored for life with in-office cystoscopies which are not effective in differentiating between inflammation and cancer. To be safe, we perform surgery on many patients which often turns out to be negative. Imagin’s i/Blue technology, given its potential speed and sensitivity, will help us assess the patient’s condition more quickly and accurately and avoid unnecessary surgery. It will also make necessary surgery more successful, ultimately saving lives and reducing medical expenses. I’m confident that using the i/Blue system will become the standard of care. I look forward to the Research Study results and I cannot wait to use this technology in treating my bladder cancer patients.”

Click here to read the full press release.

The Conversation (0)
×